Leo I Gordon

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

L. Gordon, M. Kaminski, J. Winter, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SAFETY AND PRELIMINARY EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL IN TRANSCEND NHL 001

L. Gordon, T. Farazi, M. Lunning, 2019, Blood.

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

L. Gordon, J. Kolesar, A. Evens, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytogenetic studies on patients with chronic T cell leukemia/lymphoma.

J. Winter, J. Rowley, D. Variakojis, 1984, Blood.

Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma

L. Gordon, M. Tallman, C. Nabhan, 2002, Leukemia & lymphoma.

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.

L. Gordon, J. Winter, M. Oken, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

L. Gordon, M. Tallman, T. Kuzel, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

S. Chowdhury, R. Karmali, P. Torka, 2024, Blood advances.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

J. Friedberg, A. Advani, C. Zent, 2023, Blood advances.